SecBot

SecBot
Nasdaq· Pharmaceutical Preparations· Inc. NV· CIK 0001411685

VTGN

Vistagen Therapeutics, Inc.
$0.2906 ▲ +3.79%
Prev close $0.2800
Market cap$13.2M
12-mo target$1.00 (+244.1%)
High Impact Filing (7/10)6 New Institutional Positions5 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on VTGN right now — valuation, ownership and activity at a glance.
Market Cap
$13.2M
Cap Size
Nano Cap
Inst. Holders
36 funds
Inst. Value
$1.4M
Inst. Activity
6 buys / 5 sells
Social Sentiment
60° Warm
SEC Reports
12
Price chart 30d +16.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 24, 2026 fda
Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder
Exploratory research results presented at Psych Congress 2026 in New Orleans
Aug 14, 2026 SEC
Vistagen reported Q1 FY2027 net loss of $13.0M ($0.30/share), slightly missing the $0.29 consensus. Revenue of $1.5M was
8-K — Impact 6/10
Aug 14, 2026 SEC
Vistagen reported Q1 FY2027 results with a net loss of $0.30 per share, beating consensus of -$0.36 by 16.7%, and revenu
PRESS-RELEASE — Impact 4/10
Jul 31, 2026 SEC
Vistagen Therapeutics appointed Douglas J. Williamson, M.D. to its Board of Directors effective July 29, 2026. Dr. Willi
8-K — Impact 2/10
Jul 29, 2026 Insider
Williamson Douglas J was granted 40,826 shares
Director
Jun 30, 2026 Insider
Singh Shawn was granted 36,818 shares
President and CEO @ $0.1921 ($7.1K)
Jun 30, 2026 Insider
Tressler Nick B. was granted 11,712 shares
Chief Financial Officer @ $0.1921 ($2.2K)
Jun 30, 2026 Inst.
ROYAL BANK OF CANADA — NEAR_EXIT
500 shares (—)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
DateFirmActionRatingFirm rating
Dec 17, 2025William BlairDOWNGRADEMarket Perform 51%
Dec 17, 2025Maxim GroupDOWNGRADEHold 43%
Dec 17, 2025JefferiesDOWNGRADEHold 53%
Dec 7, 2023JefferiesUPGRADEBuy 53%
Nov 14, 2023StifelINITIATEBuy 54%
Sep 5, 2023Maxim GroupMAINTAINBuy 43%
Aug 7, 2023Maxim GroupUPGRADEBuy 43%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 2026007120%
Aug 1, 2026007120%
Jul 1, 2026007120%
Jun 1, 2026007120%
May 1, 2026007120%
Apr 1, 2026007120%
Mar 1, 2026007120%
Feb 1, 2026007120%
Price targets
Where 2 covering analysts think VTGN trades over the next 12 months.
$1.00 +244.1% upside Strong Buy
Current$0.2906 Low$1.00 Median$1.00 High$1.00 2 analysts
$1.00$1.00
Analyst rating Hold· 3.0/5 as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
60°
Warm
BearishNeutralBullish
1 mentions 1 bullish 0 bearish 0 neutral
Recent posts
pennystocks Bullish 8d 22h ago
23 SEPTEMBER 2026 , 🚀 Biggest under-$5 gainers
▲ 1 · 💬 1· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
12 SEC filing reports analyzed · 1 bullish, 2 bearish, 0 mixed, 9 neutral · avg impact 4.0/10.
BEARISH8-K6/10
Vistagen reported Q1 FY2027 net loss of $13.0M ($0.30/share), slightly missing the $0.29 consensus.
Aug 14, 2026
NEUTRALPRESS-RELEASE4/10
Vistagen reported Q1 FY2027 results with a net loss of $0.30 per share, beating consensus of -$0.36
Aug 14, 2026
NEUTRAL8-K2/10
Vistagen Therapeutics appointed Douglas J. Williamson, M.D. to its Board of Directors effective July
Jul 31, 2026
BEARISH8-K7/10
Vistagen announced that its PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder faile
Jul 3, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 24, 2026
fda
Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder
Exploratory research results presented at Psych Congress 2026 in New Orleans
Sep 24, 2026
short_volume
Short Volume: VTGN — 57.9% short (6.5M / 11.2M)
Short: 6,464,091 | Exempt: 1,229,730 | TRF Vol: 11,172,562 | Short Ratio: 57.9% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: VTGN — 57.9% short (134.9M / 233.0M)
Short: 134,915,412 | Exempt: 862,293 | TRF Vol: 233,029,783 | Short Ratio: 57.9% | Off-exchange volume (dark pool + OTC)
Sep 15, 2026
short_interest_report
Short Interest: VTGN up 27% to 2.7M shares
Settlement 2026-09-15 | Days to cover: 7.64 | ≈6.10% of shares outstanding (est.)
Sep 9, 2026
short_volume
Short Volume: VTGN — 56.4% short (0.3M / 0.6M)
Short: 330,467 | Exempt: 0 | TRF Vol: 586,420 | Short Ratio: 56.4% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$-0.38$-0.38–$-0.3730.6%-1.4%0↑ 2↓$0.0B2
Next Q$-0.36$-0.37–$-0.3618.9%-1.4%0↑ 2↓$0.0B2
Current FY$-1.48$-1.50–$-1.4519.4%-1.7%0↑ 2↓$0.0B2
Next FY$-1.54$-1.54–$-1.54-4.4%+0.0%0↑ 1↓$0.0B1
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$-0.375—
7d ago$-0.370-0.005
30d ago$-0.370-0.005
60d ago$-0.375—
90d ago$-0.375—
Institutional ownership
Which big funds own VTGN (from quarterly 13F filings) and who is adding or trimming.
36 institutional holders with $1.4M total value (6,256,463 shares) as of 2026-Q2. Top holders: ROYAL, VANGUARD, TWO. Net buying activity: 6 institutions added/increased vs 5 reduced.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
ROYAL BANK OF CANADA500$0.000.0%NEAR_EXIT -76.5%
VANGUARD CAPITAL MANAGEMENT LLC1,574,200$355.8K25.1%—
TWO SIGMA INVESTMENTS, LP847,992$191.6K13.5%TRIM -32.4%
RENAISSANCE TECHNOLOGIES LLC730,500$165.1K11.7%DOUBLED +150.8%
SUSQUEHANNA INTERNATIONAL GROUP, LLP415,400$95.5K6.7%—
GEODE CAPITAL MANAGEMENT, LLC365,002$82.5K5.8%ADD +28.5%
BlackRock, Inc.345,432$78.1K5.5%—
MILLENNIUM MANAGEMENT LLC306,600$69.3K4.9%DOUBLED +118.4%
GROUP ONE TRADING LLC304,385$68.8K4.9%DOUBLED +1431.5%
VANGUARD FIDUCIARY TRUST CO217,700$49.2K3.5%—
Recent position changes
FundActionPrevCurrentChangeValue
ROYAL BANK OF CANADANEAR_EXIT2,127500-76.5%—
RENAISSANCE TECHNOLOGIES LLCDOUBLED291,300730,500+150.8%$165.1K
GROUP ONE TRADING LLCDOUBLED19,875304,385+1431.5%$68.8K
JANE STREET GROUP, LLCTRIM272,811164,827-39.6%$37.3K
UBS Group AGTRIM78,73657,830-26.6%$13.1K
OSAIC HOLDINGS, INC.DOUBLED4,13343,888+961.9%$10.1K
SIMPLEX TRADING, LLCNEAR_EXIT89,64914,295-84.1%$3.2K
CITIGROUP INCDOUBLED13,822+382100.0%$864.00
MORGAN STANLEYDOUBLED1298+29700.0%$67.00
JPMORGAN CHASE & CODOUBLED1682+412.5%$62.00
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
7 insiders, 13 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
DateInsiderTitleTypeSharesPriceValue
Jul 29, 2026Williamson Douglas JDirectorAWARD40,826——
Jun 30, 2026Singh ShawnPresident and CEOAWARD36,818$0.1921$7.1K
Jun 30, 2026Tressler Nick B.Chief Financial OfficerAWARD11,712$0.1921$2.2K
Jun 30, 2026Adler Reid G.Chief Legal OfficerAWARD36,818$0.1921$7.1K
May 18, 2026Angelov Angel SChief Medical OfficerAWARD150,000——
Apr 7, 2026Tressler Nick B.Chief Financial OfficerAWARD75,000——
Apr 7, 2026Adler Reid G.Chief Legal OfficerAWARD18,753——
Apr 7, 2026Adler Reid G.Chief Legal OfficerAWARD56,247——
Apr 7, 2026Cote Elissa S.Chief Corp Development OfficerAWARD75,000——
Apr 7, 2026Prince Joshua S.Chief Operating OfficerAWARD18,752——
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for VTGN.
Shares short
2,707,020
Settlement Sep 15, 2026
Change vs prior
+27.3%
Semi-monthly cycle
Days to cover
7.6
At avg daily volume
Of shares outstanding
≈6.1%
Estimate — not % of float
All VTGN filing & press-release reports (12)